Patients should be monitored for hypersensitivity reactions, including anaphylaxis, and the infusion should be managed accordingly.

Monitoring for Hypersensitivity and Infusion Reactions

Cerezyme should only be administered under the supervision of healthcare professionals experienced in managing hypersensitivity reactions, including anaphylaxis. Patients should be premedicated with antihistamines and/or corticosteroids if they have a history of hypersensitivity reactions. Infusion-associated reactions (IARs), such as rash, urticaria, chest discomfort, pruritus, and fever, may occur and should be managed by slowing or pausing the infusion. Patients with IgG antibodies to imiglucerase have a higher risk of hypersensitivity reactions. If severe reactions occur, administration should be discontinued, and emergency treatment, including epinephrine, should be initiated